SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnolo

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnolo

Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporti

Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporti

Raymond James analyst Martin Auster initiates coverage on iBio (NASDAQ:IBIO) with a Outperform ra

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an

iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), a clinical-stage AI-driven innov

IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to pr

iBio (AMEX:IBIO) reported quarterly losses of $(0.07) per share which missed the analyst consensus e

Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announ

IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to

iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypert

iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity a

Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate u

iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity a

Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primate

Jones Trading analyst Catherine Novack initiates coverage on iBio (NASDAQ:IBIO) with a Buy rating

iBio (NASDAQ: IBIO - Get Free Report) and Gemini Therapeutics (NASDAQ: GMTX - Get Free Report) are b

On February 27, 2026, iBio, Inc., a Delaware corporation (the "Company"), entered into an Op

The information contained in this prospectus is not complete and may be changed. These securities ma

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of pr

Vaxxinity (NASDAQ: VAXX - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both small-ca

iBio (AMEX:IBIO) reported quarterly losses of $(0.09) per share which missed the analyst consensus e

Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Prog

iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in

11,061,738 Shares of Common StockThis prospectus relates to the resale from time to time of up to 11

Vincerx Pharma (NASDAQ: VINC - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both sma

Shares of iBio, Inc. (NYSEMKT:IBIO - Get Free Report) traded up 8.3% during trading on Friday. The s

The financing was led by Frazier Life Sciences and included participation from other existing invest

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of pre

iBio (NYSE: IBIO - Get Free Report) and PyroGenesis Canada (NASDAQ: PYRGF - Get Free Report) are bot

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of pr

iBio (AMEX:IBIO) reported quarterly losses of $(0.11) per share which missed the analyst consensus e

Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-sele

iBio shares rose sharply after announcing upcoming presentations on its obesity treatment candidate